Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT)

Bank of New York Mellon Corp boosted its stake in XBiotech Inc. (NASDAQ:XBIT) by 102.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,314 shares of the biopharmaceutical company’s stock after acquiring an additional 49,863 shares during the period. Bank of New York Mellon Corp owned 0.32% of XBiotech worth $505,000 at the end of the most recent reporting period.

Separately, Empowered Funds LLC boosted its holdings in shares of XBiotech by 7.9% during the 1st quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 4,725 shares in the last quarter. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Trading Down 0.7 %

Shares of XBIT stock opened at $6.74 on Wednesday. XBiotech Inc. has a 12 month low of $3.51 and a 12 month high of $9.96. The stock has a market cap of $205.29 million, a PE ratio of -6.61 and a beta of 1.41. The company’s fifty day moving average price is $6.64 and its 200-day moving average price is $7.12.

XBiotech (NASDAQ:XBIT) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.